Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

Launched by CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD · Jan 26, 2025

Keywords

ClinConnect Summary

The XP-Real clinical trial is studying a treatment called Xeligekimab for adults with moderate to severe plaque psoriasis, a skin condition that can cause red, scaly patches. Xeligekimab was recently approved in China for patients who need more than just topical treatments. This study aims to gather information on how well Xeligekimab works and how safe it is when used in everyday medical settings, beyond the controlled environment of clinical trials.

To be eligible to participate in this study, individuals must be 18 years or older and have a confirmed diagnosis of moderate to severe plaque psoriasis. They should also be suitable candidates for Xeligekimab treatment as determined by their doctor and willing to sign a consent form. However, individuals with certain conditions, like drug-induced psoriasis or known allergies to the medication, won't be able to join. Participants will receive Xeligekimab for the first time and will help researchers understand its real-world effectiveness and safety. This study is not yet recruiting, but it represents an important step in making informed treatment decisions for psoriasis patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients who meet all the following criteria will be included in this study:
• • 1. Patients 18 years of age or older;
• • 2. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;
• • 3. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;
• • 4. Patients who are willing to sign the informed consent form.
• Exclusion Criteria:
• Patients who meet any of the following exclusion criteria will be excluded from this study:
• • 1. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);
• • 2. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;
• • 3. Patients with other contraindications specified in the prescribing information;
• • 4. Patients concurrently participating in other clinical studies;
• • 5. Patients under other conditions or circumstances that investigators do not consider appropriate to include.